Schroder Investment Management Group
OCUL icon

Schroder Investment Management Group’s Ocular Therapeutix OCUL Stock Holding History

Schroder Investment Management Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Hold
188,368
– – ﹤0.01% 944
2026
Q1 		$1.39M Buy
188,368
+129,068
+218% +$1.23M ﹤0.01% 987
2025
Q4 		$723K Buy
+59,300
New +$720K ﹤0.01% 1024

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schroder Investment Management Group's OCUL Position: Q2 2026 in Review

Schroder Investment Management Group held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 188,368 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Schroder Investment Management Group first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Schroder Investment Management Group held 188,368 shares of Ocular Therapeutix worth $1.86M as of Q2 2026.
  • Schroder Investment Management Group left its Ocular Therapeutix share count unchanged in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #944 holding.
  • Schroder Investment Management Group first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.